Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.

What was studied

This was an interim look at an ongoing phase 3 trial of povetacicept. It involved people with biopsy-proven IgA nephropathy who took stable background therapy. They were assigned by chance to povetacicept 80 mg or placebo. It was given under the skin every 4 weeks. Neither people nor doctors knew who got which. The main measure was the change in the urine protein-to-creatinine ratio at week 36.

What they found

557 people received povetacicept or placebo. The efficacy analysis used 199 people who joined early in the trial. 131 got povetacicept and 68 got placebo. By week 36, the urine ratio fell significantly more with povetacicept. Levels of galactose-deficient IgA1 fell with povetacicept and rose with placebo. Blood in the urine cleared more often with povetacicept. Side events and serious side events were similar in both groups.

What it means for patients

The authors say povetacicept cut the urine ratio significantly more than placebo. This was true by week 36 in IgA nephropathy.

Why it is not certain yet

This is a planned interim analysis of an ongoing trial. The efficacy analysis used 199 of the 557 people. The abstract gives results up to week 36 only. The abstract does not give long-term kidney results.

Source

Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.

We restate facts from the source record in our own words. The original wording belongs to its publisher.